## SEC Form 5

L

# FORM 5

Form 3 Holdings Reported.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:	3235-0362						
Estimated average burden							
hours per response:	1.0						

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL
OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940											
1. Name and Addre <u>Yonehiro Gra</u>	ess of Reporting Pers ant	son*	2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Bolt Biotherapeutics</u> , Inc. [BOLT]		ationship of Reporting Pe ( all applicable) Director Officer (give title bolow)	erson(s) to Issuer 10% Owner Other (specify below)					
(Last) C/O BOLT BIO 900 CHESAPE.	(First) THERAPEUTIC AKE DRIVE	(Middle) S, INC.	3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2022		A below) below Chief Business Officer						
(Street) REDWOOD CITY CA 94063		94063	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	ng (Check Applicable porting Person an One Reporting						
(City)	(State)	(Zip)			Person						

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr.	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially	6. Ownership Form: Direct	7. Nature of Indirect Beneficial
			8)	Amount	(A) or (D)	Price	Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)		Ownership (Instr. 4)
Common Stock	06/06/2022		Р	2,500 <sup>(1)</sup>	A	\$1.6405	3,918	D	
Common Stock	12/06/2022		Р	2,500 <sup>(1)</sup>	A	\$1.1815	6,418	D	

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		vative rities uired r osed ) r. 3, 4	Expiration Date (Month/Day/Year)		ation Date Amount of		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Shares acquired under the issuer's Employee Stock Purchase Plan.

**Remarks:** 

### /s/ William P. Quinn,

Attorney-in-Fact

02/07/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

OMB APPROVAL

OMB Number:	3235-
Estimated average b	ourden
hours per response:	

I